相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Christopher G. Przybycin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
The Molecular Pathogenesis of Hereditary Ovarian Carcinoma
Barbara M. Norquist et al.
CANCER (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer
Helen J. Mackay et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Role of Secondary Cytoreductive Surgery in Ovarian Cancer Relapse: Who Will Benefit? A Systematic Analysis of 240 Consecutive Patients
Jalid Sehouli et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study
Chunqiao Tian et al.
CANCER (2009)
Hereditary ovarian cancer
Antonio Russo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
Peter A. Argenta et al.
GYNECOLOGIC ONCOLOGY (2009)
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2009)
Hormone Therapy and Ovarian Cancer
Lina Steinrud Morch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Usha Menon et al.
LANCET ONCOLOGY (2009)
Intercepting pelvic cancer in the distal fallopian tube: Theories and realities
Christopher P. Crum
MOLECULAR ONCOLOGY (2009)
Endometrioid epithelial ovarian cancer - 20 years of prospectively collected data from a single center
Dawn J. Storey et al.
CANCER (2008)
Weekly topotecan for recurrent platinum resistant ovarian cancer
Fadi Abushahin et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
Angeles Alvarez Secord et al.
GYNECOLOGIC ONCOLOGY (2008)
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2008)
BRCAness Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
David S. P. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Gabriella Ferrandina et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer
Angela Chetrit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Risk factors for ovarian cancer: An overview with emphasis on hormonal factors
Fariba Salehi et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients
John F. Smyth et al.
CLINICAL CANCER RESEARCH (2007)
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy
Whitney A. Spannuth et al.
GYNECOLOGIC ONCOLOGY (2007)
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer
Pierluigi Benedetti Panici et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Development of an ovarian cancer symptom index - Possibilities for earlier detection
Barbara A. Goff et al.
CANCER (2007)
Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
Stephen J. Tebes et al.
GYNECOLOGIC ONCOLOGY (2007)
Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer
I. Vandenput et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Does smoking increase risk of ovarian cancer? A systematic review
Susan J. Jordan et al.
GYNECOLOGIC ONCOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Atypical presentations of carboplatin hypersensitivity reactions: Characterization and management in patients with gynecologic malignancies
Jessica N. McAlpine et al.
GYNECOLOGIC ONCOLOGY (2006)
Incidence of ovarian cancer of grand multiparous women -: A population-based study in Finland
Marianne Hinkula et al.
GYNECOLOGIC ONCOLOGY (2006)
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Jeffrey Bell et al.
GYNECOLOGIC ONCOLOGY (2006)
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
David M. Gershenson et al.
OBSTETRICS AND GYNECOLOGY (2006)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality
S Khunamornpong et al.
GYNECOLOGIC ONCOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Treatment issues in clear cell carcinoma of the ovary: A different entity?
Dimitrios Pectasides et al.
ONCOLOGIST (2006)
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
T Bonome et al.
CANCER RESEARCH (2005)
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses
CW Lee et al.
GYNECOLOGIC ONCOLOGY (2005)
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
AN Gordon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Successful carboplatin desensitization in patients with proven carboplatin allergy
R Confino-Cohen et al.
CANCER (2005)
Ovarian serous tumors of low malignant potential (Borderline tumors) -: Outcome-based study of 276 patients with long-term (≥ 5-year) follow-up
TA Longacre et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Advanced stage mucinous epithelial ovarian cancer: The Hellenic cooperative oncology group experience
D Pectasides et al.
GYNECOLOGIC ONCOLOGY (2005)
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer
DA Fishman et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2005)
Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma
G Dubernard et al.
GYNECOLOGIC ONCOLOGY (2005)
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
I Meinhold-Heerlein et al.
ONCOGENE (2005)
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation
G Singer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Endometriosis and the development of malignant tumours of the pelvis. A review of literature
T Van Gorp et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2004)
Grading ovarian serous carcinoma using a two-tier system
A Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers
SR Lakhani et al.
CLINICAL CANCER RESEARCH (2004)
Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment
V Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Carboplatin desensitization
J Choi et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
PA Vasey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions
CW Lee et al.
GYNECOLOGIC ONCOLOGY (2004)
Carcinosarcoma of the ovary - 19 years of prospective data from a single center
E Brown et al.
CANCER (2004)
Safety and efficacy of repeated monthly carboplatin desensitization
M Morgan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
What have we learned from ICON1 and ACTION?
N Colombo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
M Markman et al.
GYNECOLOGIC ONCOLOGY (2003)
Improved survival in women with BRCA-associated ovarian carcinoma
I Cass et al.
CANCER (2003)
Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma - a Gynecologic Oncology Group Study
JD Bloss et al.
GYNECOLOGIC ONCOLOGY (2003)
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
G D'Agostino et al.
GYNECOLOGIC ONCOLOGY (2003)
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
Specific keynote: Hereditary ovarian cancer: What we know
J Boyd
GYNECOLOGIC ONCOLOGY (2003)
Lymphatic spread among women with primary peritoneal carcinoma
GH Eltabbakh et al.
JOURNAL OF SURGICAL ONCOLOGY (2002)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential
MA Crispens et al.
OBSTETRICS AND GYNECOLOGY (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Menstrual and reproductive factors in relation to ovarian cancer risk
L Titus-Ernstoff et al.
BRITISH JOURNAL OF CANCER (2001)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
MJ Piccart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Histopathologic grading of ovarian carcinoma: A review and proposal
SG Silverberg
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2000)